Kihealth, Inc., a precision diagnostics company focused on disease interception and metabolic health, today announced the launch of Beta Intercept(tm), the latest version of its proprietary beta-cell cell-free DNA (cfDNA) assay designed to detect active beta-cell injury earlier and more dynamically than traditional diabetes biomarkers.